SUPN offering history
Every offering-related filing in SUPERNUS PHARMACEUTICALS, INC.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 1,000 filings back to Mar 26, 2014.
| Date | Filing | What it means | |
|---|---|---|---|
| Mar 20, 2018 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Dec 17, 2014 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Dec 4, 2014 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
SUPN offering FAQ
When did SUPN last execute an offering?
Per SEC filings, SUPERNUS PHARMACEUTICALS, INC.'s most recent priced offering document is a 8-K filed 2018-03-20. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did SUPN last announce or register an offering?
The most recent registration is a S-3 filed 2014-12-04. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.